A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

por Prins, Niels D., Harrison, John E., Chu, Hui-May, Blackburn, Kelly, Alam, John J., Scheltens, Philip
Publicado 2021

Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies

por Alam, John J., Maruff, Paul, Doctrow, Susan R., Chu, Hui-May, Conway, Jennifer, Gomperts, Stephen N., Teunissen, Charlotte
Publicado 2023

An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease

por Scheltens, Philip, Prins, Niels, Lammertsma, Adriaan, Yaqub, Maqsood, Gouw, Alida, Wink, Alle Meije, Chu, Hui‐May, van Berckel, Bart N. M., Alam, John
Publicado 2018

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

por Jiang, Ying, Alam, John J., Gomperts, Stephen N., Maruff, Paul, Lemstra, Afina W., Germann, Ursula A., Stavrides, Philip H., Darji, Sandipkumar, Malampati, Sandeep, Peddy, James, Bleiwas, Cynthia, Pawlik, Monika, Pensalfini, Anna, Yang, Dun-Sheng, Subbanna, Shivakumar, Basavarajappa, Balapal S., Smiley, John F., Gardner, Amanda, Blackburn, Kelly, Chu, Hui-May, Prins, Niels D., Teunissen, Charlotte E., Harrison, John E., Scheltens, Philip, Nixon, Ralph A.
Publicado 2022